Lifestyle factors including diet and biochemical biomarkers in acute intermittent porphyria: Results from a case-control study in northern Norway by Storjord, Elin et al.
Contents lists available at ScienceDirect
Molecular Genetics and Metabolism
journal homepage: www.elsevier.com/locate/ymgme
Lifestyle factors including diet and biochemical biomarkers in acute
intermittent porphyria: Results from a case-control study in northern
Norway
Elin Storjorda,b,c,⁎, Jim A. Dahla, Anne Landsemb,c, Judith K. Ludviksenc, Marlene B. Karlsend,e,
Bård O. Karlsenc, Ole-L. Brekkea,b
a Department of Laboratory Medicine, Nordland Hospital Trust, Bodø, Norway
b Institute of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway
c Research Laboratory, Nordland Hospital Trust, Bodø, Norway
d Regional Center for Eating Disorders, Nordland Hospital Trust, Bodø, Norway
eUnit for Health Promotion and Prevention, Meløy Municipality, Nordland, Norway








A B S T R A C T
Background: Lifestyle factors, including a low intake of carbohydrates, dieting, alcohol consumption, cigarette
smoking and stress are some of the possible triggers of attacks in acute intermittent porphyria (AIP). The in-
fluence of lifestyle factors, including energy intake, diet and alcohol consumption on the biochemical disease
activity in AIP and biochemical nutritional markers were examined.
Methods: A case-control study with 50 AIP cases and 50 controls matched for age, sex and place of residence was
performed. Dietary intake was registered using a food diary in 46 matched pairs. Symptoms, alcohol intake,
stress and other triggering factors of the last AIP attack were recorded on questionnaires. Porphyrin precursors,
liver and kidney function markers, vitamins, diabetogenic hormones and other nutritional biomarkers were
analyzed by routine methods. The Wilcoxon matched-pairs signed rank test was used to compare the cases vs.
controls. The Spearman's rank correlation coefficient was used on the cases.
Results: Increasing total energy intake was negatively correlated with the biochemical disease activity. The
intake of carbohydrates was lower than recommended, i.e., 40 and 39% of total energy intake in the AIP cases
and controls, respectively. The plasma resistin level was significantly higher (p= .03) in the symptomatic than
asymptomatic cases. Plasma insulin was lower in those with high porphobilinogen levels. The intake of sugar and
candies were higher in the AIP cases with low U-delta aminolevulinic acid (ALA) levels (p= .04). Attacks were
triggered by psychological stress (62%), physical strain (38%), food items (24%) and alcohol (32%) in the 34
symptomatic cases. Alcohol was used regularly by 88% of the cases (3.2 g ethanol/day) and 90% of the controls
(6.3 g/day), but the intake was significantly lower in symptomatic than in asymptomatic cases (p= .045).
Conclusion: A high intake of energy, sugar and candies and a higher insulin level were associated with a lower
biochemical disease activity. The resistin level was higher in the symptomatic than the asymptomatic cases. AIP
patients drink alcohol regularly, but the intake was significantly lower in the symptomatic cases.
Trial registration: ClinicalTrials.gov Identifier: NCT01617642.
1. Introduction
Acute intermittent porphyria (AIP) is an autosomal, dominant, in-
herited and rare metabolic disorder. The disease is caused by a muta-
tion in the hydroxymethyl bilan synthase (HMBS) gene, which encodes
an enzyme in the heme biosynthesis [1,2]. The prevalence of hetero-
zygous AIP mutations in the European population is between 1/75,000
to 10–20/100,000 [3,4], and about 600/100.000 in the Saltdal area in
Nordland County, Norway. A recent study has shown a higher pre-
valence of 1/1675 of the HMBS mutation in the general population in
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Europe [5]. AIP is typically asymptomatic, and approximately 90% of
those with AIP mutations never experience symptoms [2].
AIP symptoms may be triggered by mental or physical stress, al-
cohol, smoking, certain medications, infections or hormonal factors
[1–3]. Fasting and fever can also induce heme oxygenase activity; the
free heme pool is then reduced, and 5-aminolevulinic acid (ALA) syn-
thase-1 is induced [1]. Common symptoms during the acute neuro-
visceral attacks include abdominal pain, nausea, vomiting, constipa-
tion, dark red urine and muscle weakness [1,6]. Bulbar or phrenic nerve
paresis may occasionally lead to life-threatening respiratory failure
[1,7]. A high prevalence of hypertension and renal impairment has
been documented [4]. A few patients, mainly females, experience re-
current attacks. Patients who have a AIP gene mutation and have ex-
perienced symptoms of AIP are referred to as symptomatic AIP, while
those who never had symptoms are referred to as asymptomatic [1]. A
recent study by Lenglet et al. indicated oligogenic inheritance for AIP,
and this could be the reason why only a few patients are symptomatic
and why some are high and some are low excreters of ALA and PBG [8].
The first line of treatment is to remove any known triggering factor.
In hospital, intravenous infusion of glucose and/or of synthetic heme
can be administered [9]. The inhibiting effect of glucose on the heme
synthesis is probably related to peroxisome proliferator activated co-
factor 1α (PGC-1α) [10]. Liver transplantation cures AIP completely,
indicating that liver metabolism plays an important part in pathogen-
esis [11].
The dietary advice from the American Porphyria Foundation (APF)
to patients with AIP is to avoid prolonged fasting, and to have a car-
bohydrate intake of 55–60% of the total energy intake (E%). Further,
“The carbohydrates should preferably not include large amount of re-
fined sugars, but during less severe attacks intake of 300 g/day of
dextrose or other metabolizable carbohydrate is recommended.” The
Nordic Nutrition recommendations for the general population re-
commends a carbohydrate intake of 45–60 E% [12]. A recent national
diet survey (Norkost 3) showed that the average diet in Norway con-
sisted of 43–44 E% as carbohydrates [13]. Balwani et al. stated that a
“sustained adherence to a high-carbohydrate diet does not prevent at-
tack and is not recommended” [14]. Crash dieting and bariatric surgery
can precipitate porphyric attacks [15].
Ethanol may precipitate porphyric attacks in some, but not all
persons with AIP mutations, and they are advised to avoid alcohol
[16–18]. Smoking has been reported to be associated with a high fre-
quency of AIP attacks [19,20]. Low levels of vitamins and micro-
nutrients can influence overall health [12,21,22], and especially the
heme biosynthesis [23]. Repeated hemin infusions may have adverse
effects in AIP patients, possibly through a high iron load and in-
flammation [24]. Naik et al. reported that stress was a direct con-
tributor to attacks in 56% of the examined 16 AIP cases with recurrent
attacks [25].
Few studies have examined the role of the dietary intake of sugar,
total carbohydrates and other dietary factors on the disease activity in
AIP and simultaneously analyzing biochemical biomarkers. We hy-
pothesized that the total energy intake and intakes of carbohydrates,
sugar, alcohol, iron or diabetogenic hormones could be different in the
asymptomatic vs. the symptomatic AIP cases.
2. Methods
2.1. Participants and study design
A case-control study was conducted, comparing 50 AIP cases with
50 controls matched for age, sex and place of residence. Of these cases,
15 were asymptomatic and 35 were symptomatic. Most cases had the
AIP mutation W198X (n=48), while two patients had the R167W
mutation. The study was approved by the Regional Ethics Committee
for Medical and Health Research. We recruited all the participants from
September to November 2012, and all participants were examined
once. The controls were randomly selected from the registry of re-
sidents from the Norwegian Tax Administration. The exclusion criteria
for both groups were as follows: age under 18 or lacking competence to
provide consent to participate in the study. An additional exclusion
criterion for the AIP cases was absence of the AIP gene mutation, and
one person was excluded for this reason. The exclusion criteria for the
controls were also proven AIP or other porphyria, none were excluded.
Four members of the control group withdrew from the study im-
mediately before the study began and they were replaced by new
matched controls, while all AIP cases agreed to participate.
2.2. Recording of symptoms, triggering factors and diet
The cases with AIP were questioned by a medical doctor regarding
the presence or absence of AIP symptoms, the time of diagnosis, the
number and durations of attacks, and about triggering and relieving
factors during attacks. All participants were asked about their smoking
and alcohol habits, physical activity, emotional stress, medications,
nutritional supplements, present and chronic diseases and any surgeries
prior to the interview. The dietary intake was registered using a 7-day
diet logbook and was obtained from 46 cases and 46 matched controls.
Of the 35 symptomatic AIP cases, 34 filled out a diet log-book. A
clinical nutritionist instructed the participants on how to use the 7-day
diet logbook. The logbook was scanned using the Teleform program,
version 6.0 (Datascan, Oslo, Norway). Daily intakes of energy and nu-
trients were computed using the food database and software system
(KBS, version 7) developed at the Department of Nutrition, University
of Oslo. The food database (AE-10) is based mainly on the official food
composition table. Energy was calculated as (g carbohydrate× 17 kJ/
g)+ (g protein× 17 kJ/g)+ (g fat× 27 kJ/g)+ (g fiber× 8 kJ/g).
Resting metabolic rate (RMR) was calculated by Mifflin's formula, for
women: RMR (kcal)= 10×weight (kg)+ 6.25× height (cm) –
5× age (years) – 161; for men: RMR (kcal)= 10×weight
(kg)+ 6.25×height (cm) – 5× age (years). Energy requirement was
calculated multiplying RMR with a physical activity factor (PAL) [12].
The PAL factors for the participants were set by individual evaluation of
the description of their work and leisure physical activity. Energy re-
quirement was converted from kcal to kJ by ×4.184. Sugar was re-
garded as “added sugar” and did not include naturally occurring sugars.
Vitamin A was calculated as the sum of retinol and 1/12 beta-carotene.
Nutritional supplements were included in the dietary calculations. Se-
rial diastolic blood pressure was automatically measured over a
20–30min period, every second minute using a CAS 740 monitor (CAS
Medical Systems Inc., Branford, CT, USA). The body weight, length and
waist/hip-ratio were measured according to the WHO recommenda-
tions.
2.3. Blood sampling
Blood samples were obtained between 8 and 9 am by venipuncture
after an overnight fast. Vacuette citrate, EDTA and serum tubes were
used (Greiner Bio-one Gmbh, Frickenhausen, Germany). The EDTA
tubes for analyzing diabetogenic hormones in plasma were immediately
placed on crushed ice, centrifuged at 1500g for 15min at +4 °C, and
the plasma was stored at −80 °C until analysis.
2.4. Routine biochemistry tests
Hematology parameters were analyzed on a Siemens ADVIA 2120i
Hematology System (Siemens Healthcare Diagnostics Ltd., Camberly,
UK). Serum (S)-Na+, K+, Mg2+, creatinine, urine creatinine, S-iron and
other routine clinical chemistry parameters were analyzed on a
ADVIA®1800 system (Siemens Medical Solutions Diagnostics, Japan)
using reagents from Siemens Healthcare Diagnostics Ltd. The relative
estimated glomerular filtration rate (eGFR) was calculated using the
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) using
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the creatinine equation and expressed as ml/min/1.73m2 [26]. Serum
ferritin, folate and vitamin B12 were analyzed on a ADVIA Centaur® XP
system (Siemens). A BN ProSpec® nephelometer (Siemens Healthcare
Diagnostics Ltd.) was used to measure S-prealbumin and alpha-1 anti-
trypsin. Urine porphobilinogen (U-PBG) and U-ALA were analyzed
using a kit from Bio-Rad Laboratories (Munich, Germany). Total and
fractionated porphyrins were analyzed by high-performance liquid
chromatography (HPLC) as previously described [27]. Epinephrine,
norepinephrine and vanillylmandelic acid (VMA) in a random morning
urine sample were analyzed by HPLC using kits from Chromsystems
Instruments & Chemicals GmbH (Munich, Germany). Total 25-OH Vi-
tamin D were analyzed using kits from Chromsystems and an Ultimate
3000 HPLC system (Thermo Scientific, Waltham, MA, USA) equipped
with a TSQ Quantum Access MAX triple quadrupole mass spectrometry
detector.
2.5. Enzyme immunoassay
A Bio-Plex pro human diabetes 10-plex kit from Bio-Rad
Laboratories Inc. (Hercules, CA, USA) was used to measure plasma (P)-
insulin, visfatin, resistin and C-peptide in EDTA plasma on a Bio-Plex
200 system from Bio-Rad. The Enzygnost F1+2 (monoclonal) kit
(Dade Behring, Marburg GmbH, Germany) was used to analyze pro-
thrombin fragment 1+ 2 (PTF1.2) in EDTA plasma. Long-pentraxin 3
(PTX3) was analyzed by an enzyme-linked immunosorbent assay
(ELISA) kit from R&D Systems Inc. (Minneapolis, MN, USA). The optical
density was measured on a MRX microplate reader (Dynex
Technologies, Denkendorf, Germany).
2.6. Statistical analyses
The sample consisted initially of 50 cases with AIP and 50 controls
matched for age, sex and residence. The dietary data arise from
(n=46) AIP-cases and their 46 matched controls. When comparing
groups of AIP cases with high (> 1.5) and low (≤1.5 μmol U-PBG/
mmol creatinine) U-PBG levels and high (> 3.9) and low
(≤3.9 μmol U-ALA/mmol creatinine) ALA levels, we used data from all
47 AIP cases that had filled in the dietary logbook. We used the
Wilcoxon matched-pairs signed rank test on the matched case-control
data. The Spearman's rank correlation coefficient was calculated, giving
an r and two-tailed p. The Mann-Whitney U test was used on non-
matched data, i.e., on symptomatic vs. asymptomatic cases. The
Fischer's exact test was used on categorical variables. Statistical sig-
nificance was considered at p < .05. The statistical analysis was per-
formed using Prism version 6.0 from GraphPad Software Inc. (CA,
USA).
3. Results
3.1. Baseline characteristics of cases with acute intermittent porphyria and
matched controls
The baseline characteristics of the study population, which con-
sisted of AIP cases and controls matched for age, sex and place of re-
sidence, are shown in Table 1. Most variables were similar in the two
groups (Table 1). Of the 50 controls and 50 AIP cases, 6 and 10 persons,
respectively, were current smokers (p= .55) [26]. Of the 34 sympto-
matic AIP cases, 15% had experienced one AIP attack ever, and 85%
have had more than one porphyria attack. Some of them have had more
than twenty AIP attacks during their life. Of the 34 symptomatic cases
50% had been treated with glucose intravenously and 21% with Nor-
mosang intravenously, during their AIP attacks. None of the AIP cases
were under an AIP attack, and none were having glucose or Normosang
treatment at the time of study.
Overweight defined as BMI 25–29.9, was found in 52% of the AIP
cases and 38% of the matched controls. Similarly, 24% of the cases and
30% of the controls had obesity (BMI≥ 30). Of the 50 controls and 50
cases, 3 controls and 4 cases had diabetes mellitus. No significant dif-
ferences in the frequency of inflammatory diseases were observed, ex-
cept for a near-significant difference in the number of persons with gout
[26]. Statins were used by 7 AIP cases and 8 of their matched controls.
However, only 5 of 46 (11%) of the AIP cases had an adequate total
energy intake, i.e. 89% had a too low energy intake according to the
dietary logbook. Of the controls, 4 of 46 (9%) had an adequate total
energy intake, while 42 (91%) had a too low energy intake.
3.2. Dietary intake of carbohydrates, sugar, protein, fat and fatty acids in
cases with acute intermittent porphyria and matched controls
The dietary intake of carbohydrates as E% was similar, but lower
than the Nordic 2012 recommendations in 78% of the AIP cases and
91% of the controls (Fig. 1A). The intake of added sugar was similar
between the groups but was higher than the recommendations in 37%
of cases and 26% of the controls (Fig. 1B). The intake of protein
(Fig. 1C), fiber (Fig. 1D), total fat (Fig. 1E), saturated fatty acids (SFA,
Fig. 1F) and monounsaturated fatty acids (MUFA, Fig. 1G) was similar
in the cases and controls. However, the intake of fiber given as g/MJ
(Fig. 1D) was lower and the intakes of total fat and SFA given as E%
(Fig. 1E, F) were higher than recommended. The intake of poly-
unsaturated fatty acids (PUFA) was significantly lower (p= .04) in
cases than in the controls, and 15% of cases and 9% of controls had a
lower intake of PUFA given as E% intake than recommended (Fig. 1H).
3.3. Dietary intakes of vitamin D, calcium, vitamin B12, folate and the
corresponding serum levels in cases with acute intermittent porphyria and
matched controls
The intake of vitamin D was similar in the two groups, but below the
recommended 10 μg/day in 63% of the AIP cases and 54% of the
controls (Fig. 2A). The intake of calcium was insufficient in 65% of
cases and 50% of controls. The total S-calcium levels were within the
normal reference limits in 98% of cases and 96% of the controls. The
vitamin B12 intake was similar and sufficient in both groups (Fig. 1E),
and S-vitamin B12 levels were above the lower reference limit in both
cases and controls (Fig. 1F). One case and one control used vitamin B12
injections (Fig. 1F). In comparison, the intake of folate was lower than
recommended in 82% of cases and 78% of the controls, when con-
sidering men and postmenopausal women (Fig. 2G), and 88% of cases
and 78% of controls, when considering premenopausal women. How-
ever, only 8% of the controls had S-folate levels below the lower re-
ference limit (Fig. 2H).
3.4. Intake of vitamin supplements
Doctor-prescribed regular vitamin B12 injections and vitamin D
medications was used by 2% of cases and 2% of controls (App Table A).
Of the cases, 2% used isotretinoin (vitamin A), and 2% of controls used
magnesium supplements (App. Table A). Iron medication was taken by
6% of cases and 12% of the controls. Over-the-counter vitamin sup-
plements were taken by several cases and controls, including vitamin B,
vitamin D, multi vitamins, vitamin K and herbal remedies (Appendix
Table A).
3.5. Homocysteine levels, kidney function, calcium, albumin, parathyroid
hormone and porphobilinogen levels in asymptomatic and symptomatic cases
and matched controls
The homocysteine levels in plasma were significantly higher in the
symptomatic AIP cases compared to their matched controls, but were
similar in the asymptomatic cases and controls (Fig. 3A). The kidney
function given as eGFR was significantly lower (p= .0008) in the
symptomatic than in the asymptomatic AIP cases (Fig. 3B). Diastolic
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blood pressure was significantly higher in the symptomatic than in the
asymptomatic cases (Fig. 3C), while the U-epinephrine level was lower
(Fig. 3D). S-calcium and albumin were significantly lower (Fig. 3E, F)
and PTH levels in plasma were significantly higher (Fig. 3G) in the
symptomatic cases than in the asymptomatic cases. As expected, U-PBG
levels were significantly higher in the asymptomatic and symptomatic
cases compared with their respective matched controls (Fig. 3H).
Table 1
Baseline characteristics of the study population.
Characteristics Controls Cases p RIa
(Norway)
RDAb, AI (Am.)
25%ile Median 75%ile 25%ile Median 75%ile
Age, years 31.8 52 68 31.8 52 68.3 0.39
Height, cm 163 172 179 164 171 180 0.84
Weight, kg 71.5 80.3 91.4 69.4 81 92.3 0.6
BMI, kg/m2 23.8 26.8 30 25 27 29.8 0.92 20–25c 18.5–24.9c
Hip circumference, cm 93.9 98.8 106 93.9 99.4 107 0.75
Waist circumference, cm 89 94.6 104 89.3 94.8 106 0.84 ≤93/≤79d,e
Waist/Hip –ratio 0.9 0.97 1.01 0.88 0.98 1.02 > 0.99
RMRf Wg, kJ/day 5054 5448 6125 4971 5515 6268 0.67
Energy req.h, Wg kJ/day 9117 9690 10,933 7786 9590 11,343 0.45
Energy intake Wg, kJ/day 5532 7266 9001 5978 7141 7947 0.84
RMRf Mi, kJ/day 6335 7289 7540 6519 7234 7728 0.12
Energy req.h, Mi kJ/day 10,899 11,983 13,539 11,288 13,188 13,866 0.30
Energy intake Mi, kJ/day 7735 8988 11,111 8209 9383 12,058 0.53
RMRf all, kJ/day 5581 6318 7355 5535 6523 7397 0.40
Energy req.h, all, kJ/day 9786 11,016 12,426 9678 11,527 13,334 0.81
Energy intake all, kJ/day 6996 8367 10,621 7099 8162 10,763 0.72
Protein, g/day 65.6 80.6 105 68.8 77.6 98.9 0.92 56/46e
Fat, g/day 72 86.8 112 70 84.5 115 0.76
Saturated fat, g/day 29 36.8 43.9 28.7 36 47.6 0.38
C-MUFAjl, m, g/day 23 29.1 36.9 21.9 28.4 37.1 0.58
C-PUFAk, g/day 12.5 16.7 20.7 10.8 13.8 20.5 0.19
Cholesterol, mg/day 264 356 434 280 383 483 0.56
Carbohydrates, g/day 156 190 211 166 201 248 0.12 130
Sugar, g/day 27.3 36.6 50 30.7 42.8 56 0.18
Vitamin A, μg/day 645 929 1074 707 909 1160 0.25
Retinol, μg/day 515 701 893 568 750 945 0.31 900/700e 900/700e
B-carotene, μg/day 1194 1875 3104 1101 1728 2368 0.69
Tocopherol, mg/day 8.0 14.2 20.8 9.35 12.3 17.3 0.79 10/8e 15
Thiamin, mg/day 1.00 1.31 1.85 1.01 1.32 1.92 0.94 l 1.2/1.1e
Riboflavin, mg/day 1.27 1.55 2.42 1.26 1.66 2.52 0.77 m 1.3/1.1e
Vitamin B6, mg/day 1.03 1.44 2.13 1.12 1.49 2.32 0.67 1.5/1.2n 1.3n
Vitamin C, mg/day 44.8 63.5 145 51 73.5 134 0.72 75 90/75e
Fe, mg/day 7.8 9.4 14.4 7.7 9.8 14.3 0.48 9/15e,o 8/18e,p
Potassium, mg/day 2716 3537 4325 2637 3201 4108 0.49 3500/3100k 4700
Mg, mg/day 283 332 412 258 289 406 0.33 350/280 e 420/320q,e
Zn, mg/day 8.0 10.6 13.3 7.9 10.5 15.8 0.39 9/7e 11/8e
Se, μg/day 34.5 49.5 73.3 37.5 52.5 75.5 0.77 60/50e 55
Cu, mg/day 0.81 1.1 1.34 0.87 1.08 1.61 0.59 0.9 0.9
Phosphorus, mg/day 1147 1457 1733 1156 1392 1799 0.84 600r 700
Sugar, E%s 6.3 7.5 10.6 6.1 9.1 12.4 0.1 <10 <10
Alcohol, E%s 0 2.5 4.8 0 0.95 4.1 0.55 <5
The data represent median values and interquartile ranges; 25%ile and 75%ile. The data were analyzed using the Wilcoxon matched-pairs signed-rank test on the AIP
cases (n=46) versus matched controls on all data except age, height, weight, BMI, hip circumference, waist circumference and Waist/Hip-ratio (n=50) AIP cases
and 50 matched controls. Of the 46 matched pairs 20 are women and 26 are men. The p-values are exact, two-tailed.
a RI=Recommended intake, from Norwegian guidelines on diet, nutrition and physical activity, The Norwegian Directorate of Health, 2014.
b RDA=Recommended Dietary Allowance, AI=Adequate intake, from Dietary Guidelines for Americans. 8th Edition 2015–2020, January 2016, US Department
of Health and Human Services and US Department of Agriculture.
c Normal body mass index, BMI. For persons above 70 years (y): 22–27.
d Indicates low risk level metabolic disease.
e Men/Women.
f RMR, Resting metabolic rate calculated by Mifflin's formula.
g W=women.
h Energy requirement=RMR* PAL.
i M=men.
j C-MUFA=Cis-mono unsaturated fatty acids, kC-PUFA=Cis-poly unsaturated fatty acids.
l Thiamin: M: 1.4 mg/d for 18–30 y 1.3: 31–60 y, 1.2:> 60. W: 1.1 mg/d for 18–60 y, 1.0: > 60 y.
m Riboflavin; M: 1.6 mg/d for 18–30 y, 1.5: 31–60 y, 1.4: 61–74, 1.3:> 75 y, W: 1.3 mg/d for 18–30 y, 1.2 > 30 y.
n Vitamin B6 Nordic rec.: W > 60 y: 1.2, n Vitamin B6 American rec.: W > 51 y: 1.5, M > 51 y: 1.7.
o Iron, Women:> 61 y: 9.
p Iron, Women, American rec.> 51 y: 8.
q Mg: M:19–30: 400W:19–30 y: 310.
r P: 18–20 y: 700.
s E%=% of total energy intake.
E. Storjord et al. Molecular Genetics and Metabolism xxx (xxxx) xxx–xxx
4
3.6. Intake of sugar/candies, carbohydrates, protein, meat and alcohol and
plasma resistin and alpha-1 antitrypsin levels in asymptomatic and
symptomatic cases and matched controls
The intake of sugar/candies and carbohydrates was not significantly
different between the symptomatic and asymptomatic AIP cases
(Fig. 4A, B). The median intake of protein was close to be significantly
different (p= .052) between the symptomatic and asymptomatic cases
(Fig. 4C). The intake of meat given as g/day was significantly lower in
the symptomatic than in the asymptomatic cases (Fig. 4D). The P-re-
sistin level were significantly higher (p= .03) in the symptomatic than
in the asymptomatic AIP cases and were significantly lower (p= .004)
in the asymptomatic cases than in their matched controls (Fig. 4E).
Interestingly, the intake of alcohol both given as g/day (Fig. 4G) and as
E% (Fig. 4F) was significantly lower in the symptomatic than in the
asymptomatic AIP cases. However, the alcohol intake was not sig-
nificantly different from the matched controls (Fig. 3E, F).
3.7. Alcohol intake, cigarette smoking and intake of carbohydrates, added
sugar and sugar/candies in acute intermittent porphyria cases with low and
high levels of porphyrin precursors
We next examined if lifestyle factors, including alcohol, cigarette
smoking and intake of carbohydrates and sugar/candies in the diet
were different in the AIP cases with low and high biochemical disease
activity. The intake of alcohol given as g/day (Fig. 5A) and E% (Fig. 5B)
was similar in the AIP cases with low and high U-PBG levels. The
number of cigarettes smoked per day (Fig. 5C), fat intake as E%
(Fig. 5D), carbohydrate intake as E% (Fig. 5E) and added sugar intake
as E% (Fig. 5F) were not different in the AIP cases with high and low U-
Fig. 1. The dietary intake of carbohydrates, added
sugar, protein, fiber, total fat, saturated fatty acids
(SFA), monounsaturated fatty acids (MUFA) and
polyunsaturated fatty acids (PUFA) in 46 acute in-
termittent porphyria (AIP) cases (Case) compared
with their matched controls (Control, n= 46). The
dietary intake of (A) carbohydrates, (B) added sugar,
(C) protein, (E) total fat, (F) saturated fatty acids
(SFA), (G) MUFA and (H) PUFA are expressed as % of
total energy intake, except for fiber intake (g/MJ).
The dietary intake was calculated from a seven-day
dietary logbook. The results are shown as scatter-
plots with the median. The two horizontal dotted
gridlines show the recommended intake (RI)-interval
for adults above 18 years for carbohydrate, protein,
fiber, total fat, MUFA and PUFA. The one horizontal
dotted gridline for added sugar and SFA indicates the
upper recommended intake level. All dietary re-
commendations in the figure are from the current
Norwegian guidelines on diet, nutrition and physical
activity. The data were analyzed using the Wilcoxon
matched-pair signed rank test. The p-values are
exact, two-tailed.
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PBG levels. Interestingly, the intake of sugar/candies given as g/day
(Fig. 5G) was significantly higher (p= .04) in the AIP cases with a low
U-ALA levels (Fig. 5G). However, the sugar/candies intake was not
significantly different in the AIP cases with low and high PBG levels
(Fig. 5H).
3.8. Meat intake and serum iron levels, folate intake and folate levels, and
creatinine and homocysteine levels in acute intermittent porphyria cases with
low and high levels of porphyrin precursors
The intake of meat given as g/day (Fig. 6A) and folate given as μg/
day (Fig. 6C) was similar in the AIP cases with low and high U-PBG
levels. The S-iron levels (Fig. 6B) were close to be significantly different
(p= .053) between the AIP cases with low and high U-PBG levels. The
intake of folate (Fig. 6C) and the S-folate levels (Fig. 6D) were similar in
the AIP cases with low and high PBG levels. However, the S-creatinine
(Fig. 6E) and P-homocysteine levels (Fig. 6F) were significantly higher
in the AIP cases with high U-PBG levels than in those with low PBG
levels.
3.9. Serum glucose, plasma insulin, glucose/insulin ratio, pre-albumin and
plasma C-peptide levels in acute intermittent porphyria cases with low and
high levels of porphyrin precursors
The glucose levels were similar in the AIP cases with low and high
U-PBG levels (Fig. 7A). The median plasma insulin level was sig-
nificantly (p= .02) higher (Fig. 7B) and the glucose/insulin-ratio
(Fig. 7C) was significantly lower (p= .02) in the AIP cases with low
compared to those with high U-PBG levels. The pre-albumin levels
(Fig. 6D) and plasma C-peptide levels (Fig. 6E) were similar in the AIP
cases with low and high U-PBG levels. The C-peptide levels were not
significantly different between the cases with low and high U-ALA
Fig. 2. Dietary intake of vitamin D, calcium, vitamin
B12 and folate and the corresponding serum (S) le-
vels in acute intermittent porphyria (AIP) cases and
matched controls. The intake of (A) vitamin D, (C)
calcium, (E) vitamin B12 and (G) folate in AIP cases
(n=46) was compared with their matched controls
(n=46). The dietary intakes were calculated from a
seven-day dietary logbook and expressed as μg/day,
except for the calcium intake (mg/day). The hor-
izontal dotted gridline shows the recommended in-
take (RI) for adults above 18 years for the following:
(A) vitamin D intake: 10 μg/day, but for persons>
75 years, the RI is 20 μg/day; (C) calcium intake:
800mg/day, but for persons 18–20 years, the RI is
900mg/day, and for postmenopausal women, a
supplement of calcium of 500–1000mg/day might
reduce age-related bone loss and (E) Vitamin B12
intake: 2 μg/day, (G) The RI for folate intake is
300 μg/day for postmenopausal women (open cir-
cles) and men (black squares). The upper horizontal
dot-line gridline in panel (G) shows the RI of folate
400 μg/day for women in fertile age (open triangles).
All dietary recommendations are from the current
Norwegian guidelines on diet, nutrition and physical
activity. The serum level of (B) total 25-OH vitamin
D was analyzed by liquid chromatography with
tandem mass spectrometry (LC-MS/MS) and ex-
pressed as nmol/l. The serum levels of (D) total
calcium (mmol/l), (F) S-vitamin B12 (pg/ml) and
(H) S-folate (nmol/l) were analyzed using standard
biochemical methods and expressed as mmol/l, pg/
ml and nmol/l, respectively. “The control and the
AIP case who received regular vitamin B12 injections
are marked as black dots.” The results are shown as
scatter-plots with the median. The horizontal dotted
gridlines indicate the reference limits for: (B) S-25
OH vitamin D total (50 nmol/l), (D) S-calcium
(2.15–2.55mmol/l), (F) S-vitamin B12 (150 pmol/l)
and (H) S-folate (7 nmol/l). The data were analyzed
using the Wilcoxon matched-pair signed rank test.
The p-values are exact, two-tailed.
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levels (Fig. 7F). The AIP cases (n= 2) who received anti-diabetic
medications are indicated with black dots (Fig. 7). When the p values
for the comparison of biomarkers in the AIP cases with low and high U-
PBG were calculated after the exclusion of those who received anti-
diabetic medication, the results were; S-glucose (p= .11) as before, P-
insulin (p= .04) and Glucose/Insulin-ratio (p= .04).
3.10. Porphyrin precursors, serum cholesterol, triglycerides and other
biochemical biomarkers in cases with acute intermittent porphyria and
controls
The levels of all porphyrins and porphyrin precursors were, as ex-
pected, significantly higher in the AIP cases than in the controls
(Table 2). The S-total cholesterol, S-LDL cholesterol, and S-triglyceride
levels were significantly higher in AIP cases than in the controls
(Table 2). The S-phosphate levels were lower in the cases than in the
controls (Table 2). The VMA levels in random urine samples were sig-
nificantly lower in the AIP cases than in the controls, but the levels of U-
norephinephrine and U-ephineprine were similar. All biomarkers of
iron deficiency, including hemoglobin and erythrocyte numbers, were
similar in the AIP cases compared to those of the controls (Table 2). The
S-CDT%, S-electrolytes and cortisol levels were similar in cases and
controls (Table 2).
3.11. Correlations between dietary intake, alcohol, smoking, biochemical
biomarkers of kidney and liver function, and porphyrin precursors in cases
with acute intermittent porphyria
The U-PBG levels correlated significantly and positively with P-
homocysteine, S-creatinine, PTX3, HDL and total cholesterol levels
Fig. 3. Levels of homocysteine, kidney function,
diastolic blood pressure, urine (U)-epinephrine,
serum (S)-calcium, S-albumin, plasma (P)-PTH and
U-porphobilinogen (U-PBG) levels in asymptomatic
(Asympt.) and symptomatic (Sympt.) acute inter-
mittent porphyria (AIP) cases (n=50) and matched
controls (Control, n= 50). The analytes were ana-
lyzed using standard biochemical methods. (A) P-
homocysteine is expressed as μmol/l, (B) relative
eGFR (estimated glomerular filtration rate) chronic
kidney disease (CKD-EPI) as ml/min/1.73m2 with
the creatinine equation, (C) diastolic blood pressure
as mm Hg, (D) U-epinephrine as nmol/mmol creati-
nine, (E) S-calcium as mmol/l, (F) S-albumin as g/l,
(G) P-PTH as pmol/l and (H) U-PBG as μmol PBG/
mmol creatinine. Serial diastolic blood pressure was
automatically measured over a 20–30min period,
every second minute using a CAS 740 blood pressure
monitor. The paired case-control data were analyzed
using the Wilcoxon matched-pair signed rank test.
The asymptomatic and symptomatic AIP cases were
compared using the Mann-Whitney U test.
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(Fig. 8). U-PBG levels correlated significantly and negatively with pre-
albumin, total energy intake and PUFA intake (Fig. 8). In comparison,
U-ALA correlated significantly and negatively with S-pre-albumin and
sugar/candies intake (Fig. 8). U-ALA correlated significantly and posi-
tively with smoking given as cigarettes smoked/day (Fig. 8). Further-
more, the inflammatory marker PTX3 correlated significantly and ne-
gatively with the carbohydrate intake given as g/day, but not with
carbohydrates as E% (Fig. 8). As expected, the alcohol intake correlated
positively and significantly with the CDT% (data not shown).
3.12. Correlations between biomarkers of glucose metabolism, diabetogenic
hormones and biomarkers of disease activity in cases with acute intermittent
porphyria
The porphyrin precursor U-PBG correlated positively and
significantly with U-ALA and S-iron levels (Fig. 9). U-ALA correlated
significantly and positively with S-cortisol levels (Fig. 9). Both U-PBG
and U-ALA correlated with P-PTF1.2 levels. B-reticulocytes, P-leptin, P-
ghrelin and P-resistin also correlated positively and significantly with
PTF1.2 levels (Fig. 9). Furthermore, resistin and U-VMA showed a po-
sitive correlation. Plasma resistin levels in the cases were not correlated
with BMI (data not shown). As expected, S-glucose correlated sig-
nificantly and positively with HbA1c levels (Fig. 9).
3.13. Triggering factors for attacks and symptoms in cases with acute
intermittent porphyria
The most frequent AIP symptoms and signs were abdominal pain
(91%), dark/red urine (80%), tiredness (71%), muscle ache (60%) and
muscle weakness (60%), followed by vomiting, headaches, decreased
Fig. 4. Dietary intake of sugar and candies, carbo-
hydrates, protein, meat, alcohol and urine-porpho-
bilinogen (U-PBG) levels in asymptomatic (Asympt.)
and symptomatic (Sympt.) acute intermittent por-
phyria (AIP) cases and matched controls (Control).
(A) Intake of sugar and candies is given as g/day, (B)
carbohydrate intake as g/day, (C) protein intake as
g/day, (D) meat intake as g/day, (E) P-resistin as pg/
ml, and the AIP cases and controls who received anti-
diabetic medications are indicated by black dots, (F)
S-alpha-1 antitrypsin as g/l, (G) alcohol intake as g/
day and (H) alcohol intake as % of total energy in-
take. The dietary intake was calculated from a seven-
day dietary logbook from 46 matched pairs, i.e., 12
asymptomatic and 34 symptomatic cases and 12 and
34 matched controls. S-alpha-1 antitrypsin was
analyzed using standard biochemical methods and P-
resistin was analyzed using a Diabetes 10-plex assay
in 15 asymptomatic and 35 symptomatic cases and
matched controls. The paired case-control data were
analyzed using the Wilcoxon matched-pair signed
rank test. The asymptomatic and symptomatic AIP
cases were compared using the Mann-Whitney U
test.
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awareness, palpitations, psychological symptoms, constipation, paresis
and epilepsy (Table 3). The most prevalent triggering factors for por-
phyric attack in the AIP cases were psychological stress (62%), followed
by work environment (41%), which was described in most cases as
stress at work or stressful working (Table 3). Physical strain were the
third most prevalent trigger (38%), followed by other diseases in-
cluding infections, sleep deprivation, food items, hunger, alcohol,
dieting and medications. Cigarette smoking was a triggering factor in 6
% of the symptomatic AIP cases. The menstrual cycle was a trigger for
17% of the attacks in female AIP cases. Of the asymptomatic and
symptomatic AIP males, 75% and 69%, respectively, had finished one
year of military service.
4. Discussion
To our knowledge, this is the first report that both analyzes the
dietary intake using a dietary logbook and simultaneously analyzes
biochemical nutritional markers and diabetogenic hormones in blood
samples in AIP cases and matched controls. The results indicate that the
intake of slow-release carbohydrates was lower, and the intakes of
sugar and saturated fatty acids was higher than recommended for the
Nordic countries, both in the AIP cases and controls. Vitamin D defi-
ciency was the most common vitamin deficiency in both the cases and
controls. The intake of alcohol was unexpectedly high in the AIP cases,
but lower in the symptomatic than in the asymptomatic cases. Insulin
was higher in the cases with low U-PBG levels. Plasma resistin levels
were higher in the symptomatic than the asymptomatic cases. These
Fig. 5. Lifestyle factors, including (A, B) alcohol in-
take, (C) cigarette smoking, (D) total fat intake, and
(E) intake of carbohydrates and (F) total sugar in
acute intermittent porphyria (AIP) cases with low
urine (U)-porphobilinogen (PBG) compared with AIP
cases with high U-PBG levels. (G) Intake of sugar and
candies in AIP cases with low (< 3.9) U-delta-ami-
nolevulinic acid (ALA) compared with AIP cases with
high U-ALA (> 3.9 μmol ALA/mmol creatinine), i.e.,
the reference limit for this assay. A low U-PBG level
was defined as values≤ 1.5 μmol PBG/mmol crea-
tinine, i.e., the reference limit for this assay. The
dietary components were calculated from a seven-
day dietary logbook. The results are shown as
scatter-plots with the median. The two horizontal
dotted gridlines on total fat intake (D) and carbo-
hydrate intake (E) indicate the recommended intake
(RI) range, and the horizontal dotted gridline (F) for
added sugar intake indicates the upper RI, as % of
total energy for adults above 18 years. All dietary
recommendations are from the current Norwegian
guidelines on diet, nutrition and physical activity.
The data were analyzed using the Mann-Whitney U
test. The P-values are exact, two-tailed.
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findings may have several explanations and implications.
The energy intake was sufficient in all AIP cases and controls since
the BMI results indicate that half of the AIP cases and about 4 out of 10
of the matched controls in this study were overweight. Similarly, 1 out
of 4 of the cases and 3 out of 10 of the controls had obesity in line with
the high and increasing frequency of obesity in Norway. However,
when the energy intake was calculated from the diet logbook, most
cases and controls had an insufficient energy intake. However, the
dietary intake is probably slightly (17%) underreported according to
unpublished data from a validation study of the 7- day diet log book
among adults (personal communication from A.M. Wetting Johansen,
the Department of Nutrition, Univ. of Oslo). Interestingly, an increasing
energy intake was negatively correlated with the U-PBG levels in the
AIP cases suggesting that the total energy intake affects the biochemical
disease activity also in periods with no dieting.
The intake of carbohydrates in most AIP cases and controls was
lower than the recommended 45–60 E% in Norway and other Nordic
countries [12,22] and in the US [21]. Thus, the AIP cases did not have a
high intake of slow-release carbohydrate foods, in line with a previous
report on 16 Spanish AIP cases [28]. In addition, the intake of added
sugar was higher than the recommended maximum 10% of total energy
intake in many AIP cases and controls, and this may lead to obesity. The
intake of sugar and candies was higher in those with low ALA levels
than in the group with high ALA levels, suggesting an effect of this
dietary factor on the biochemical disease activity. However, no differ-
ence in sugar and candies or carbohydrate intake was found between
the asymptomatic and symptomatic AIP cases. Finally, no significant
correlation was found between the intake of carbohydrates and disease
activity in the AIP cases, although a near significant correlation was
found between carbohydrate intake in g/day and U-PBG. This may be
due to a too low consumption of carbohydrates in the AIP cases, since
the carbohydrate intake in two previous studies were up to 500 g/day
[29,30], compared to a median intake of 201 g carbohydrates/day in
the cases in this report. However, the previous finding that the AIP
cases who acquired type 2 diabetes mellitus did not have symptoms of
AIP supports the protective role of elevated glucose levels [31]. Fur-
thermore, glucose reduced the synthesis of ALA and PBG in a mouse
model of AIP [10]. However, the plasma glucose level is regulated by
multiple hormones, including insulin, resistin, glucagon, cortisol and
catecholamines. A previous study indicated that the S-glucose level was
unchanged, but the fasting levels of insulin were higher and the glu-
cagon was lower in AIP mice than in wild-type mice [32]. We pre-
viously found that the fasting insulin levels were decreased in the
symptomatic AIP cases compared to the matched controls, but no dif-
ference was found between asymptomatic and symptomatic cases [26].
This report suggests that the fasting insulin was lower and the glucose/
insulin ratio was higher in the AIP cases with high compared to the
group with low U-PBG level. This finding, and the report by Handschin
et al. [10] indicating an inhibitory effect of insulin on porphyrin pre-
cursor levels in mice, suggests that glucose should be administered
together with insulin during porphyric attacks.
The higher resistin level in the symptomatic than the asymptomatic
cases, and the positive correlation with leptin levels may indicate that
inflammation [26], adipokines and hormones affecting insulin
Fig. 6. Intake of meat and folate and the serum (S)
levels of iron, folate, plasma (P) homocysteine and
kidney function markers in acute intermittent por-
phyria (AIP) cases with low U-porphobilinogen
(PBG) compared with AIP cases with high U-PBG.
Low U-PBG was defined as ≤1.5 μmol PBG/mmol
creatinine, corresponding to the upper reference
limit. The dietary components were calculated from
a seven-day dietary logbook including intake of (A)
meat and (C) folate. (B) S-iron, (D) S-folate, (E) S-
creatinine and (F) P-homocysteine levels were ana-
lyzed using standard biochemical assays and the re-
sults are shown as scatter-plots with the median. The
two horizontal dotted gridlines in panel B indicates
the reference values for S-iron (9–34 μmol/l) and
black dots indicate AIP cases who received iron
supplements. (C) The RI for folate intake is 300 μg/
day for postmenopausal women (open circles) and
men (black squares). The upper horizontal dot-line
gridline in panel (C) shows the RI of folate 400 μg/
day for women in fertile age (open triangles). All
dietary recommendations in the figure are from the
current Norwegian guidelines on diet, nutrition and
physical activity. The horizontal dotted gridlines in-
dicate the reference value for: (D) S-folate
(> 7 nmol/l), (E) S-creatinine in women (lower line,
90 μmol/l) and for men (upper line, 105 μmol/l), and
(F) P-homocysteine (> 15 μmol/l) and a black dot
indicates the AIP case who received B12 injections.
The data were analyzed using the Mann-Whitney U
test. The P-values are exact, two-tailed.
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resistance may possibly be involved in a high disease activity [33].
However, we have no explanation for these differences, but this
indicate that the role of hormones regulating glucose uptake such re-
quires further investigation. Acute inflammation can trigger AIP attacks
[1], but the inflammation observed as increased resistin levels found in
the AIP cases could be an effect of the AIP disease itself, since it was
observed in periods between attacks and outside acute inflammation.
Resistin activates TLR4 on macrophages and increases the release of
cytokines [34]. Furthermore, increased resistin levels is probably not an
effect of other inflammatory diseases, as we did not find enhanced
frequency in inflammatory diseases that could explain the difference in
cytokines [26]. On the other hand, the slightly higher frequency of
smoking, higher LDL levels and lower prealbumin levels indicating liver
inflammation in the AIP cases, may partly explain the enhanced in-
flammation [26]. Another possible pathway from AIP with increased
ALA, PBG and porphyrins to inflammation could be that ALA, PBG and
porphyrins cause tissue damage that creates elevated cytokines [26].
Additionally, damage associated patterns (DAMPS) such as elevated
uric acid due to reduced kidney function in some AIP cases could lead to
cytokine production [26].
The intake of fat, and especially saturated fatty acids, was higher
than recommended in both the AIP cases and controls and is associated
with enhanced risk of cardiovascular disease [35]. The higher choles-
terol levels in the cases can not be explained by a higher intake of SFA
in the AIP cases, since the intake of SFA was elevated in both groups.
Replacement of dietary saturated fats with PUFA normally reduces
cholesterol levels and the CVD risk [35], and the lower PUFA intake in
the AIP cases, may partly explain the higher total cholesterol and tri-
glyceride levels in the AIP cases than in the controls. The intake of
protein was within the national recommendations both in the AIP cases
and the controls. The fiber intake was similar but was lower than re-
commended in both AIP cases and controls, in line with a previous
report [28]. The intake of meat was lower in the AIP cases than in the
controls. This may have several reasons, but we speculate that this may
be due to the enhanced prevalence of reduced kidney function and
maybe gout [26] in the AIP cases since patients with gout are advised to
reduce the intake of purine-rich foods [36].
The intake of some vitamins, including vitamin D, was insufficient
in many AIP cases and controls, and vitamin D deficiency was common
in both groups. This may partly explain the enhanced PTH levels in
some AIP cases, although reduced kidney function may also increase
PTH levels [37]. Vitamin D deficiency is very common in Norway due
to insufficient dietary sources and a lack of sunlight in northern Norway
[38]. Vitamin D deficiency may have several negative effects, including
increased risk of osteoporosis [37]. S-iron was close to be significantly
higher in the AIP cases with high PBG levels, but iron deficiency was
rare in the AIP cases. The homocysteine levels were increased in the
symptomatic AIP cases compared to their matched controls, but this
was probably not due to a severe deficiency of folate or vitamin B12.
The increased homocysteine levels in the symptomatic cases was most
likely due to reduced kidney function since homocysteine and creati-
nine levels were highly and positively correlated. However, a deficiency
Fig. 7. Glucose, insulin, glucose/insulin ratio, pre-
albumin and C-peptide levels in acute intermittent
porphyria (AIP) cases with low U-porphobilinogen
(PBG) compared with acute intermittent porphyria
(AIP) cases with high U-PBG. (A) serum glucose le-
vels (mmol/l), (B) insulin (pg/ml), (C) glucose/in-
sulin ratio (mmol/l/pg/ml), (D) S-pre-albumin (g/l),
(E) C-peptide levels (pg/ml) in AIP cases with low
(n= 20) and high (n= 30) levels of porphyrin pre-
cursors in urine. The black dots in panels A, B, C, E
and F, indicate AIP cases who received anti-diabetic
medications. A low U-porphobilinogen (PBG) level
was defined as ≤1.5 μmol PBG/mmol creatinine,
i.e., the reference value in urine. (F) C-peptide levels
in AIP cases with low U-delta aminolevulinic acid
(ALA) defined as<3.9 μmol ALA/mmol creatinine
(n= 25). S-glucose and pre-albumin were analyzed
using standard biochemical assays, while the other
markers were analyzed using a Bio-PlexPro Human
Diabetes 10-plex immunoassay from Bio-Rad. The
results are shown as scatter-plots with the median.
The two horizontal dotted gridlines in panel (D) pre-
albumin are the normal reference values for men
(black squares) and for women>50 years (open
circles). For women<50 years (open inversed tri-
angles) the reference values are 0.23–0.39 g/l (dot-
line gridline). The data were analyzed using the
Mann-Whitney U test. The P-values are exact, two-
tailed.
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of vitamin B1 and B6 cannot be excluded since they were not measured.
The diastolic blood pressure and PTH was higher and S-albumin and
calcium were slightly lower in the symptomatic compared to the
asymptomatic AIP cases, probably also due to a reduced kidney func-
tion in the symptomatic AIP cases.
The use of alcohol in the AIP cases was much higher than expected,
and was higher than the generally recommended upper limit of 1 al-
cohol unit (12 g) per day in a few cases. However, the alcohol intake
was significantly lower in the symptomatic AIP cases than in the
asymptomatic cases. Since alcohol had triggered attacks in 32% of the
AIP cases in line with a previous study [18], we speculate that the
symptomatic cases reduced the intake to avoid attacks. No correlation
was found between the alcohol intake and disease activity. The finding
that most AIP cases in this study used moderate amounts of alcohol
regularly may indicate that a regular, but moderate intake of alcohol is
less porphyrinogenic than an acute intake of alcohol [17,39]. However,
the alcohol intake observed in both the AIP cases and controls, may
partially hide the real impact of alcohol in the AIP group. AIP cases are
advised to avoid alcohol. According to a WHO report from 2016, the
mean total alcohol intake per capita in Norwegian adults above
15 years age was 7.5 l pure alcohol per year, compared to 9.8, 9.8, 6.3
and 7.3 in the whole European region, the US, the African and the
Western Pacific Regions, respectively [40]. The mean total alcohol in-
take was 5.7 and 4.3 l per year in the controls for the asymptomatic and
symptomatic AIP cases, respectively, and 6.1 and 3.1 l in the asymp-
tomatic and symptomatic AIP cases, respectively. This indicates that the
alcohol intake in the cases was not high compared to the rest of Norway
and other countries. Furthermore, the alcohol habits vary between
different countries, and different individuals, and this should be kept in
mind when our results from Norway are being evaluated. It is well
known that alcohol is toxic to the liver and is associated with enhanced
risk of hepatocellular carcinoma (HCC) and liver cirrhosis [41].
Table 2
Biomarker levels in acute intermittent porphyria cases and controls.
Controls Cases p
25%ile Median 75%ile 25%ile Median 75%ile
U-ALAa, μmol/mmol creatinine 1.6 1.9 2.3 2.4 3.9 7.0 < 0.0001
U-PBGb, μmol/mmol creatinine 0.3 0.4 0.5 0.9 2.6 8.5 < 0.0001
U-Total porphyrins, nmol/mmol creatinine 4.4 6.8 11 8.5 26 83 <0.0001
U-Uroporphyrins, nmol/mmol creatinine 1 1.25 1.7 1.3 2.8 19.7 < 0.0001
U-Heptaporphyrins, nmol/mmol creatinine 0.2 0.3 0.5 0.3 0.7 1.3 < 0.0001
U-Hexaporphyrins, nmol/mmol creatinine 0.1 0.1 0.3 0.0 0.2 0.7 0.045
U-Pentaporphyrins, nmol/mmol creatinine 0.0 0.1 0.2 0.1 0.4 1.4 < 0.0001
U-Coproporphyrins, nmol/mmol creatinine 3.0 4.5 8.8 6.3 14 44 <0.0001
S-Total Cholesterol, mmol/l 4.6 5.1 5.7 5.1 5.7 6.4 0.002
S-LDLc-Cholesterol, mmol/l 2.3 3.1 3.7 3.0 3.5 3.9 0.02
S-HDLd-Cholesterol, mmol/l 1.3 1.5 1.8 1.1 1.4 1.8 0.50
S-Triglycerides, mmol/l 0.7 1.0 1.4 1.0 1.2 1.85 0.01
S-CDTe, % 1.2 1.4 1.7 1.3 1.5 1.6 0.49
B-Hemoglobin, g/dl 13.7 14.4 15.3 13.6 15.0 15.8 0.19
B-EVFf 0.40 0.42 0.45 0.41 0.43 0.47 0.08
Erc-MCVg, fl 85 87 91 86 89 93 0.18
Erc-MCHh, pg 29 30 31 29 30 32 0.57
B-EPKi, ×1012/l 4.6 4.9 5.1 4.7 5 5.3 0.25
Erc-Reticulocytes, % 0.8 0.9 1.2 0.8 1 1.2 0.47
Rtkc-CHrj, pg 32.6 33.7 34.7 32.7 33.9 35 0.71
Erc-Hypok, % 0.1 0.2 0.3 0.1 0.2 0.4 0.59
B-Platelets, ×109/l 224 266 299 194 243 287 0.05
S-Ferritin, μg/l 49 120 186 57 111 222 0.76
S-Iron, μmol/l 13 19 22 14 17 19 0.81
S-TIBCl, μmol/l 59 62 70 63 67 75 0.06
S-Soluble transferrin receptor, mg/l 1.0 1.2 1.5 1.0 1.23 1.5 0.70
S-Sodium, mmol/l 140 142 143 140 141 142 0.20
S-Potassium, mmol/l 4.1 4.2 4.4 4.2 4.3 4.5 0.11
S-Magnesium, mmol/l 0.85 0.90 0.93 0.88 0.91 0.96 0.31
S-Phosphate, mmol/l 0.99 1.13 1.25 0.87 1.06 1.21 0.03
S-Cortisol, nmol/l 385 460 587 406 549 584 0.45
U-Norepinephrine, nmol/mmol creatinine 12 16 23 9 14 20 0.09
U-Epinephrine, nmol/mmol creatinine 1.75 2.0 3.25 1.0 2.0 3.0 0.37
U-VMAm, μmol/mmol creatinine 1.1 1.6 2.1 0.8 1.3 1.9 0.01
The data represent the median values and interquartile range; 25 percentile (25%-ile) and 75 percentile (75%-ile).
Wilcoxon's matched-pairs signed-rank test was used on all case-control data in this table. N=50 matched pairs.




e S-CDT%=percentage of carbohydrate-deficient transferrin.
f B-EVF=Whole blood erythrocyte volume fraction.
g Erc-MCV=Erythrocyte mean corpuscular volume.
h Erc-MCH=Erythrocyte mean corpuscular hemoglobin.
i B-EPK=Whole blood erythrocyte-particle concentration.
j Rtkc-Chr=Reticulocyte hemoglobin content.
k Erc-Hypo=Percentage of hypochromic red cells.
l S-TIBC=Serum-total iron-binding capacity.
m U-VMA=Urine vanillylmandelic acid.
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However, in the study by Innala et al., none of the AIP cases developing
HCC were abusing alcohol [42]. This indicates that the general re-
commendation of no or a very low alcohol intake in AIP cases should be
continued.
Psychological stress and physical strain was reported as triggers of
attacks in 62% and 38%, respectively, of the symptomatic AIP cases.
This result is in line with the report by Naik et al. who reported that
56% of patients with acute hepatic porphyrias said that stress, mainly
emotional stress or caused by work, was a direct contributing factor to
their acute attacks [25]. Several stress hormones were analyzed in this
study, outside of AIP attacks, but only the levels of VMA were decreased
in the AIP cases compared to the controls. In comparison, the levels of
epinephrine and norepinephrine were similar in the cases and controls.
We have no explanation for these findings, but speculate that the ca-
techolamine release or VMA formation might be slightly decreased in
the AIP cases in periods outside attacks. Stress may also affect the levels
of stress hormones, which in turn affect the metabolism of glucose and
fat. A previous report by Pozo et al. showed reduced levels of urine
adrenal steroid hormones, including cortisol metabolites, in AIP cases
compared to controls [43]. In this report, S-cortisol levels were similar
in the AIP cases and controls, but urine metabolites of cortisol were not
examined.
This report indicates that 2%, 6% and 20% of the AIP cases used
porphyrinogenic, probably porphyrinogenic or possibly porphyrino-
genic medications, respectively. Furthermore, 29% of the symptomatic
cases reported that medications had triggered attacks. This is an un-
expected finding since it is well known that correct medication is im-
portant in AIP cases and that many medications are porphyrinogenic
[44]. The most likely explanation for this is that some medical doctors
still have limited knowledge about AIP despite repeated information
given regarding correct medication.
Current smoking was slightly more common among the AIP cases
than among the controls. However, smoking had triggered attacks in
only 6 % of the symptomatic AIP cases in this report. Among the
asymptomatic and symptomatic cases, one out of five were smoking
tobacco. Furthermore, the number of cigarettes smoked per day was
correlated with the biochemical disease activity of ALA, but not of PBG,
in the AIP cases. This is partially in agreement with Bylesjo et al. who
reported that smoking was associated with a high AIP attack frequency
[20]. In addition, even low cigarette usage is associated with an en-
hanced risk of several diseases, including lung cancer, coronary heart
disease and stroke and should be avoided [45].
The kidney function was lower in the symptomatic AIP cases, which
is in agreement with several previous reports indicating that the por-
phyrin precursors are toxic to the kidney tubuli and endothelial cells
causing a chronic tubulointerstitial nephropathy [5,6]. In line with this,
the S-albumin and P-PTH levels were slightly lower and higher in the
cases than controls, respectively. Furthermore, the pre-albumin levels
were reduced in the AIP cases, indicating reduced liver function, mal-
nutrition or inflammation of the liver [26,46].
This study has several limitations that might have affected the re-
sults. First, most of the AIP cases had the same AIP mutation. Second,
many different parameters were analyzed, implying that the risk of false
positive results in the statistical analysis is high. Third, the number of
AIP cases was limited to 50, mainly due to the rarity of the disease.
However, to our knowledge this is the first report on the role of dietary
factors in AIP cases using a dietary logbook and biochemical analysis in
blood samples for many of the same nutrients and vitamins. The re-
gistration of food intake, however, may have been underreported since
the reported energy intake was lower than the calculated energy
Fig. 8. Correlation matrix of porphyrin precursors, diet, alcohol, cigarette smoking, diet-related biomarkers and PTX3 in the acute intermittent porphyria (AIP) cases
(n=47). The data in the left lower part are Spearman's correlation coefficients, in the AIP cases (n=47), r≥ 0.29 and r≤−0.29 (blue color). The correlation
matrix shows pairwise correlations of the different variables. In the upper right part the corresponding significant p values (p < .05) are indicated by red color. The
variables included are: urine porphobilinogen ratio (U-PBG); urine 5-aminolevulinic acid ratio (ALA); S-creatinine (Creat.); P-homocysteine (Homoc.); S-pre-albumin
(Prealb.); S-total cholesterol (Cholest.); S-high-density lipoprotein (HDL); S-triglycerides (Trigl.); intake of energy kJ/day (Energy KJ); carbohydrates g/day (Carb. g);
Carbohydrates % of total energy (Carb. %); sugar/candy intake g/day (Sug/Cand.); saturated fatty acids (SFA) (g/day); polyunsaturated fatty acids (PUFA) g/day;
alcohol g/day (Alco. g); current smoking of cigarettes per day (Cig.); and pentraxin 3 (PTX3), ng/ml. (For interpretation of the references to color in this figure
legend, the reader is referred to the web version of this article.)
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requirement, and the RMR-factor (energy intake divided by RMR) was
lower than expected from their activity level in some of the cases and
controls [47]. However, the underreporting seems to be similar in both
cases and controls, indicating that the intake in the cases and controls
can still be compared. Another limitation is that the comparison against
the reference energy and nutritional recommendations are for Norway,
Nordic Countries and Americans, and it may, thus, be questioned with
respect to the extent that this issue may limit the generalization of
Fig. 9. Correlation matrix of porphyrin precursor and biomarkers of glucose metabolism- and diet-related biomarkers, prothrombin factor 1+ 2 (PTF1.2) and CDT%.
In the lower left part are Spearman correlation coefficients, r, in the acute intermittent porphyria group (n= 47), r≥ 0.29 and r≤−0.29 (blue color). The
correlation matrix shows pairwise correlations of the different markers. In the upper right part are the corresponding significant p values (p < .05), which are
indicated by red color. The variables included are the following: urine porphobilinogen ratio (PBG); urine 5-aminolevulinic acid ratio (ALA); Erc-Reticulocytes %
(Retic.); S-iron (Iron); S-glucose (glucose); B-HbA1c (HbA1c); S-cortisol (cortisol); urine vanillylmandelic acid (VMA); P-insulin (Insulin); S-glucose/P-insulin ratio
(G/ins-r); P-visfatin (Visfatin); P-leptin (Leptin); P-resistin (Resistin); P-ghrelin (Ghrelin); P-gastrointestinal peptide (GIP); P-prothrombin F1+2 (PTF1.2) and
percentage of carbohydrate deficient transferrin (CDT%). (For interpretation of the references to color in this figure legend, the reader is referred to the web version
of this article.)
Table 3
Symptoms and triggering factors of attacks in acute intermittent porphyria cases.
Symptoms during AIP attacksa % Triggering factors of attacksb % Triggering factors of attacks,womenc % Military service accomplishedd %
Abdominal pain 91 Psychological stress 62 Birth control pills 0 Asymptomatic men 75
Dark/red urine 80 Work environment (mainly stress) 41 Menstrual cycle 17 Symptomatic men 69
Tiredness 71 Physical strain 38 Menstrual cycle, first day 17
Muscle ache 60 Other disease 32 Menstrual cycle, ovulation 0
Muscle weakness 60 Sleep deprivation 32 Menstrual cycle, other 0
Othere 43 Alcohol 32
Vomiting 43 Medication 29
Headaches 43 Food items 24
Decreased sensibility 40 Hunger 24
Palpitations 40 Dieting 9
Psychological symptoms 26 Other (alternative medications) 6
Constipation 23 Smoking 6
Paresis 17
Epilepsy 6
The data were obtained from interviews done by medical doctors and questionnaires.
a % of AIP symptomatic cases, (n=35), 18 women, 17 men.
b % of AIP symptomatic cases, (n=34), one data missing.
c % of (n= 18) symptomatic women, regarding menstrual cycle.
d % of 12 asymptomatic and % of 16 symptomatic men regarding military service (one of 17 symptomatic men had missing data on question on military service).
e e.g: Diarrhea, visual disturbances, fecal incontinence, impaired memory.
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results to other countries, for instance, in Asia and Southern Europe,
etc. However, the dietary recommendations do not vary much between
the Nordic countries, European countries and the US [48], indicating
that the comparison of intakes in the AIP case and control group with
the recommended intake is valid for many countries. Furthermore, the
comparison of the intake in the AIP case and control groups is also
valid, although the actual dietary habits may vary in different coun-
tries. The differences in dietary habits between the Nordic area [12],
the Mediterranean area [49], and other parts of the world should be
kept in mind when our results are generalized to other AIP patients. In
general, the individual dietary pattern should be assessed when in-
dividualized dietary advice are given to AIP patients. Furthermore, the
biomarkers on glucose metabolism were possibly affected by the anti-
diabetic medication used by two AIP cases..
In summary, several lifestyle factors, including total energy intake,
alcohol, stress and medications may affect the disease activity of AIP
cases. The distinction between slow-release carbohydrates and added
sugar is not always precisely explained to the AIP patients, leaving
some of them on a diet high in added sugar which may lead to obesity.
Resistin levels were higher in the symptomatic than asymptomatic AIP
cases, and insulin was higher in the cases with low U-PBG levels sug-
gesting that hormones regulating glucose uptake may be disturbed in
AIP. Several of these lifestyle factors, including diet, alcohol intake and
stress, are known to affect the expression of genes through epigenetic
changes. A recent study suggested oligogenic inheritance in AIP,
pointing to several factors that dictate who manifests symptoms [8].
Future studies should therefore examine the role of other related mu-
tations and other epigenetic changes that could explain why only a few
of those with an AIP mutation have symptoms of the disease, while
most cases are asymptomatic.
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Appendix A. Appendix Table A Porphyrinogenic medications, vitamin supplements, dietary supplements and herbal remedies in acute
intermittent porphyria cases and controls
Controls n (%) Cases n (%) p
Medications
PSPa medications 4 (8) 10 (20) 0.15
PRPb medications 12 (24) 3 (6) 0.02
Pc medications 1 (2) 1 (2) 1.00
Medications containing vitamins, Mg or iron
Vitamin B12 injection 1 (2) 1 (2) 1.00
Etalpha (1α(OH)-vitamin D3) 1 (2) 1 (2) 1.00
Isotretinoin (Vitamin A) 0 (0) 1 (2) 1.00
Magnesium 4 (8) 0 (0) 0.12
Iron 6 (12) 3 (6) 0.27
Supplements
Vitamin B 6 (12) 4 (8) 0.74
Vitamin C 5 (10) 2 (4) 0.44
Vitamin D 4 (8) 5 (10) 1.00
Multi-vitamins 4 (8) 5 (10) 1.00
Calcium 3 (6) 2 (4) 1.00
Vitamin K 0 (0) 1 (2) 1.00
Fish oil 18 (36) 15 (30) 0.67
Persons using herbal remedies 8 (16) 7 (14) 1.00
The data were obtained from questionnaires from all participants, and from the 7-day diet logbook from n=47 cases and 48 controls, and are given as n and
% of AIP cases (n= 50) and of their age-, sex- and place of residence-matched controls (n=50).
The herbal remedies are not counted in the PSP, PRP and P-data. Herbal remedies containing vitamins, calcium, magnesium or iron are also counted in
supplements where applicable. Two-tailed P values were calculated using Fischers exact test.
a PSP=Possibly porphyrinogenic medication.
b PRP=Probably porphyrinogenic medication.
c P=Porphyrinogenic medication.
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Appendix Fig. A. Possible pathways from lifestyle factors to increased porphyrin precursor levels and symptoms in acute intermittent porphyria. The possible role of
lifestyle factors in the biochemical disease activity and symptoms in AIP cases are summarized. An AIP mutation is the prerequisite for AIP disease. To acquire
elevated porphyrin precursor levels often requires several triggering factors at the same time such as stress, physical strain, dieting, alcohol and/or porphyrinogenic
medications (red box), which may partly explain the low manifestation rate of symptoms in the AIP cases. Many factors may contribute to the worsening or
improvement of porphyrin precursor levels and symptoms, such as genetic and epigenetic modifiers (blue box), the intensity of triggers as the level of protective
factors such as a higher sugar intake and relaxation. Other diseases, such as diabetes mellitus, may also protect those with an AIP mutation. High levels of ALA and
PBG affects the nervous system, the liver and kidney and result in abdominal pain, and vomiting etc. during the acute nevrovisceral attacks. Enhanced U-PBG levels
are possibly associated with lower insulin levels. Resistin levels are higher in the symptomatic than the asymptomatic cases, and are associated with inflammation. As
illustrated, most AIP cases tolerate different amounts of single triggering factors and probably have sufficient protective factors (marked in green) to avoid an
increase in the porphyrin precursors and attacks. This conforms to what we have found, for example, with alcohol intake, since there was no difference in the PBG
levels in those who drank more or less alcohol.
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